ACR Convergence 2025| Video: Rheum for Everyone, Episode 26—Ableism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Tocilizumab After Ultra-Short Course Steroids Promising for Newly Diagnosed GCA

Marilynn Larkin  |  

NEW YORK (Reuters Health)—Tocilizumab induced a slow and lasting remission after an ultra-short pulse (three days) of steroids in newly diagnosed giant cell arteritis (GCA) patients, a proof-of-concept trial shows.1 His early research on cytokines and glucocorticoids led Peter Villiger, MD, of Medical Center Monbijou, Bern, Switzerland, to find ways to reduce steroid use, he…

Generally Favorable Outcomes 6 Months After COVID-Linked Inflammatory Syndrome in Kids

Reuters Staff  |  

NEW YORK (Reuters Health)—A six-month assessment of children with pediatric inflammatory multisystem syndrome temporally associated with COVID-19 disease (PIMS-TS) show generally favorable outcomes, but also a range of lingering issues. Cardiac, gastrointestinal, renal, hematology and otolaryngology problems largely resolved at six months, but muscular fatigue and emotional lability were common. Long-term, serious end-organ damage occurred…

U.S. to Announce New Warning on J&J Coronavirus Vaccine for Guillain-Barré Syndrome

Reuters Staff  |  

(Reuters)—The U.S. Food & Drug Administration (FDA) is expected to announce a new warning on Johnson & Johnson’s (J&J’s) coronavirus vaccine related to a rare autoimmune disorder, The Washington Post reported on Monday, citing four people familiar with the matter.1 According to The Post, about 100 preliminary reports of Guillain-Barré syndrome have been detected in the…

Patients with Rheumatic Disease May Experience Flares after SARS-CoV-2 Vaccination

Linda Carroll  |  

(Reuters Health)—Among a group of New York patients with rheumatic diseases who received a SARS-CoV-2 vaccine, nearly one in six experienced disease flares after getting their shots, a new study finds.1 A survey of more than 1,100 patients who had received at least one vaccine dose revealed that 14.9% experienced flares. Among the 654 who…

Rare Disease Sheds Light on the Origins of Lupus

  |  

Patients with the rare DNASE1L3 biallelic null mutation present with childhood-onset disease that resembles lupus. This observation prompted research into how abnormalities in the enzyme DNASE1L3 are associated with lupus, with researchers finding autoantibody-mediated impairment of DNASE1L3 activity may be a common non-genetic mechanism leads to anti-dsDNA autoreactivity in SLE.

The ACR/Vasculitis Foundation Release Three New Guidelines for Treatment of Vasculitis

  |  

ATLANTA—The American College of Rheumatology (ACR), in partnership with the Vasculitis Foundation (VF), released three new guidelines for the treatment and management of systemic vasculitis. Vasculitis is a group of about 20 rare diseases that have inflammation of blood vessels in common, which can restrict blood flow and damage vital organs. The three guidelines cover…

Advocates for Arthritis 2021 Applications Now Open

  |  

The ACR is accepting applications for this year’s Advocates for Arthritis event, which will be held virtually on Sept. 27–28. This annual event brings together patients and rheumatology professionals to advocate for our subspecialty on Capitol Hill. Applications are also open for the Advocacy 101 program, which provides advocacy training for ACR/ARP members. Apply today…